Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma

J Natl Cancer Inst. 1993 May 19;85(10):823-5. doi: 10.1093/jnci/85.10.823.

Authors

J J Rusthoven¹, E Eisenhauer, J Mazurka, H Hirte, G O'Connell, A Muldal, H X Lu, N Onetto, K Swenerton, J Jeffrey

Affiliation

¹ Hamilton Regional Cancer Center, Ontario, Canada.

PMID: 8487328
DOI: 10.1093/jnci/85.10.823

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I

MeSH terms

Carboplatin / administration & dosage*
Carboplatin / adverse effects
Female
Humans
Interleukin-3 / administration & dosage*
Interleukin-3 / adverse effects
Neoplasm Recurrence, Local / drug therapy*
Neutrophils / drug effects
Ovarian Neoplasms / blood
Ovarian Neoplasms / drug therapy*
Platelet Count / drug effects
Recombinant Proteins / administration & dosage

Substances

Interleukin-3
Recombinant Proteins
Carboplatin